Tami: I’m the kind of person who likes to know what I’m fighting, and the information just wasn’t there. I couldn’t find it anywhere, and what I did find, I later learned, was mostly incorrect.

Onscreen text: Tami was diagnosed with high-risk myelofibrosis (MF) in 2015.

Onscreen text: THE PURPLE CHAIR

Chuck: It was a very rare disease and just not a whole lot known about it.

Onscreen text: Chuck was diagnosed with polycythemia vera (PV) in 2014.

Onscreen text: A RARE, CHRONIC BLOOD CANCER DIAGNOSIS CAN RAISE A LOT OF QUESTIONS.

Onscreen text: What is this?

Tami: I've never even heard of it before, so I didn't know what to do. I didn't know what questions to ask. I didn't really understand what was going on, and I really felt lost.

Chuck: I didn't know anybody else who had the disease. I didn't know really who to turn to for help.

Donna: I kind of tried to pretend that it didn't exist…I didn't want my sons to know until I knew more of the journey and the hills that I might have to climb.

Onscreen text: Donna was diagnosed with PV in 2020.

Mark: I knew it was serious. I told my parents, who were very concerned, very nervous. They had never heard of it.

Onscreen text: Mark was diagnosed with intermediate-risk MF in 2017.

Onscreen text: Polycythemia vera and myelofibrosis are rare, chronic blood cancers that are part of a group of diseases called myeloproliferative neoplasms (MPNs).

Donna: I think you just feel so alone.

Onscreen text: BUT ASKING QUESTIONS IS THE FIRST STEP IN FINDING A PATH FORWARD.

Donna: Several things helped me cope with my diagnosis. One was prayer, a lot of that. The second was research and finding the information.

Mark: Research did allow me to sit down and have a conversation with people about my condition. And, you know, that part of it, you know, was great.

Chuck: It was like a light clicked in my head. I don’t have to be a victim of this. The only way that I could understand what's going on in my body is to be better educated.

Tami: Your doctor is the person who's going to be able to help you the most, who's going to have the education that will help you.

Onscreen text: WITH TIME, INFORMATION CAN LEAD TO INSPIRATION…

Donna: I used to ask, why me? And then I developed the philosophy of why not me?

Tami: This is my life. I've never let anybody else be in charge of it before. I'm taking control. I'm going to find out what I need to know.

Onscreen text: DETERMINATION CAN EMPOWER DECISIONS…

Tami: You face challenges each and every day. Everybody does. It's how you deal with it. Everybody has to be responsible for themselves.

Donna: And when you're handed something like this, it causes your priorities to be refocused.

Donna: I have to take charge of my own health. I have to know as much as I possibly can know. For those who feel they need second and sometimes third opinions, that's what they might need to do.

Onscreen text: AND SELF-ADVOCACY CAN STRENGTHEN THE SEARCH FOR SUPPORT.

Chuck: As I began to realize that this disease was progressing, I realized that I needed to see a specialist to find out exactly what was going on.

Donna: And I remember the nurse practitioner saying, “what kind of specialist have you seen?” and I named them for her, and she said, well, you now have a new specialist you need to see.

Donna: I said, OK, what do we do next? And she said, we get you an appointment immediately. I had already been through so many emotions of anger, frustration, worry, concern. I was ready for information, and I wanted to be able to get help.

Onscreen text: NEXT EPISODE

Onscreen text: Brought to you by Jakafi^® (ruxolitinib)

Onscreen text and narrator: Jakafi^® (ruxolitinib) is the first FDA-approved prescription medicine for adults with PV who have already taken a medicine called hydroxyurea (HU) and it did not work well enough or they could not tolerate it. Jakafi is also the first FDA-approved prescription medicine for adults with intermediate or high-risk MF.

Onscreen text and narrator: Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi^® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information at Jakafi.com, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Onscreen text: LEARN MORE ABOUT JAKAFI^® (ruxolitinib)

This video is sponsored by Incyte Corporation. Jakafi and the Jakafi logo are registered trademarks of Incyte.

© 2022, Incyte Corporation. MAT-JAK-02975  02/22